{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:50:35Z","timestamp":1791402635824,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"am","delay-in-days":290,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jbspin.2022.105457","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T12:05:21Z","timestamp":1663243521000},"page":"105457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer"],"prefix":"10.1016","volume":"90","author":[{"given":"Ang\u00e9lique","family":"Melia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Fockens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Sfumato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Zemmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Madroszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lafforgue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2022.105457_bib0205","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2022.105457_bib0210","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.jbspin.2022.105457_bib0215","doi-asserted-by":"crossref","first-page":"102546","DOI":"10.1016\/j.jaut.2020.102546","article-title":"Modulating the wayward T cell: new horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer","volume":"115","author":"Calabrese","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2022.105457_bib0220","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.40043","article-title":"Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer","volume":"69","author":"Suarez-Almazor","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105457_bib0225","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jbspin.2022.105457_bib0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rdc.2016.09.007","article-title":"Immune-related adverse effects of cancer immunotherapy\u00a0\u2014\u00a0implications for rheumatology","volume":"43","author":"Cappelli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2022.105457_bib0235","first-page":"182","article-title":"Psoriatic arthritis due to nivolumab administration a case report and review of the literature","volume":"23","author":"Sapalidis","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.jbspin.2022.105457_bib0240","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jbspin.2022.105457_bib0245","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2022.105457_bib0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105457_bib0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2022.105457_bib0260","article-title":"Features of polymyalgia rheumatica\u2013like syndrome after immune checkpoint inhibitor therapy","author":"Martin de Fremont","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105457_bib0265","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105457_bib0270","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2022.105457_bib0275","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1574886313666180508122332","article-title":"Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature","volume":"13","author":"Benfaremo","year":"2018","journal-title":"CDS"},{"key":"10.1016\/j.jbspin.2022.105457_bib0280","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105457_bib0285","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor\u2013induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2022.105457_bib0290","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2022.105457_bib0295","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jbspin.2022.105457_bib0300","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","author":"Zhong","year":"2020","journal-title":"Asia-Pac J Clin Oncol [Internet]"},{"key":"10.1016\/j.jbspin.2022.105457_bib0305","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3904\/kjim.2019.060","article-title":"Rheumatic complications in cancer patients treated with immune checkpoint inhibitors","volume":"34","author":"Lee","year":"2019","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jbspin.2022.105457_bib0310","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1007\/s10067-020-05162-9","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a novel clinical entity with striking similarities to seronegative rheumatoid arthritis","volume":"39","author":"Liu","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105457_bib0315","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/medicines7110068","article-title":"Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature","volume":"7","author":"Manzo","year":"2020","journal-title":"Medicines"},{"key":"10.1016\/j.jbspin.2022.105457_bib0320","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.jbspin.2022.105457_bib0325","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1078155216667635","article-title":"Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors","volume":"23","author":"Firwana","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jbspin.2022.105457_bib0330","series-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"National Cancer Institute","year":"2017"},{"key":"10.1016\/j.jbspin.2022.105457_bib0335","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbspin.2022.105457_bib0340","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/1756-185X.13444","article-title":"Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy","volume":"22","author":"Liew","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2022.105457_bib0345","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2022.105457_bib0350","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105457_bib0355","doi-asserted-by":"crossref","first-page":"102595","DOI":"10.1016\/j.autrev.2020.102595","article-title":"Rheumatic immune-related adverse events associated with cancer immunotherapy: a nationwide multi-center cohort","volume":"19","author":"Roberts","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2022.105457_bib0360","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211006963","article-title":"Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis","volume":"13","author":"Verspohl","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2022.105457_bib0365","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2022.105457_bib0370","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2022.105457_bib0375","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death\u20131 pathway inhibitors among patients with non\u2013small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.jbspin.2022.105457_bib0380","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2022.105457_bib0385","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbspin.2022.105457_bib0390","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J Exp Med"},{"key":"10.1016\/j.jbspin.2022.105457_bib0395","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.jbspin.2022.105457_bib0400","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.semarthrit.2018.02.011","article-title":"Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen","volume":"48","author":"Cappelli","year":"2018","journal-title":"Semin Arthritis Rheum"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X22001178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:29:13Z","timestamp":1761150553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X22001178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1297319X22001178"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105457","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2022.105457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105457"}}